// App-Quantinova.ai

TPS2609 : A Phase I/Ib study of MEK162 (binimetinib), a MEK inhibitor, in combination with carboplatin and pemetrexed in patients with non-squamous NSCLC.

Researchers

Presenter

  • Safiya Karim

Principal Investigators

  • Ronald Feld

  • Natasha B. Leighl

  • Frances A. Shepherd

  • Penelope Ann Bradbury

  • Geoffrey Liu

  • Donna M. Graham

Medical Centers

  • University of Saskatchewan, Saskatoon, SK, Canada

  • Princess Margaret Hospital, Toronto, ON, Canada

  • Princess Margaret Cancer Centre, University Health Network, Division of Medical Oncology and Hematology, Toronto, ON, Canada

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Ontario Cancer Institute, Princess Margaret Hospital, Toronto, ON, Canada

  • Queen's University Belfast, Belfast, United Kingdom

Locations

  • Canada

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Retinal vein occlusion

  • Non Small Cell Lung cancer

Biomarkers

  • B-Raf proto-oncogene, serine/threonine kinase

  • Epidermal growth factor receptor

  • GTPase Nras

  • KRAS proto-oncogene, GTPase

  • RAS mutation

Drug/Treatment

  • Binimetinib

  • Carboplatin

  • Pemetrexed

Outcome

  • N/A

Study Design

  • Dose Escalation

  • Cohort

Phase

  • I

Study Id's

  • NCT02185690

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved